Immutep’s ADS count is expected to decline from approximately 32.8 million to approximately 1.64 million when its revised ADS ratio takes effect on September 28, 2026. The change is intended to help the Nasdaq-listed ADSs satisfy the $1.00 minimum bid requirement before the company’s October 26, 2026 compliance deadline.
Key Highlights
- Immutep’s 1,473,721,306 ordinary shares will remain unchanged after the ADS adjustment.
- BNY will aggregate fractional ADS entitlements and distribute cash without deducting a fee.
- Holders of physical ADR certificates should contact BNY or their broker about the conversion.
Immutep Limited (NASDAQ: IMMP) is a biotechnology company. Its ADS count is expected to move from approximately 32.8 million to approximately 1.64 million when a revised ADS ratio takes effect on September 28, 2026. The change is aimed at helping the Nasdaq-listed ADSs meet the $1.00 minimum bid requirement before the October 26, 2026 compliance deadline.
Revised ADS Basis Begins September 28
Trading on the Nasdaq Global Market will begin under the revised basis on September 28, 2026. Immutep’s ordinary-share count will remain 1,473,721,306, and the adjustment will not change the number of ordinary shares issued. The ticker IMMP stays unchanged, while the ADS security receives a new CUSIP and ISIN; the ordinary-share ISIN remains unchanged. The change does not alter Immutep’s capital structure, cash position or clinical development programmes.
Nasdaq Compliance Test Sets the Timeline
Nasdaq notified Immutep that its ADS closing bid price had remained below $1.00, creating a continued-listing compliance issue under Nasdaq Listing Rule 5450(a)(1). The company must bring the closing bid price to at least $1.00 for the required consecutive-business-day test before October 26, 2026. September 29, 2026 will be the first trading day counted toward that requirement. Immutep said the revised ratio was chosen to create a Margin above $1.00 rather than mirror the current ADS trading price.
FAQs
Q: What happens to Immutep ADSs on September 28?
A: Immutep’s revised ADS basis begins on September 28, 2026, and the ADS count is expected to fall from approximately 32.8 million to approximately 1.64 million. The Nasdaq ticker remains IMMP.
Q: What Nasdaq listing requirement is Immutep addressing?
A: Immutep is addressing Nasdaq’s minimum bid-price requirement for continued listing. Its ADS closing bid price must reach at least $1.00 before the October 26, 2026 compliance deadline.
Q: How will fractional Immutep ADS entitlements be handled?
A: BNY will aggregate and sell ADSs representing fractional entitlements. Cash proceeds are expected to reach eligible holders one to two days after the effective date, with no fee deducted.
Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research Reports
Disclaimer:
Kalkine Equities LLC, with Delaware File Number 4697384, Foreign Qualification Registration in California File Number 202109211078, and Texas File Number 805521396, is authorized to provide general advice only. The information on https://kalkine.com/ does not take into account any of your investment objectives, financial situation or needs. You should consider the appropriateness of advice taking into account your own objectives, financial situation and needs and seek independent financial advice before making any financial decisions. The link to our Terms and Conditions and Privacy Policy has been provided for your reference. On the date of publishing the reports (mentioned on the website), employees and/or associates of Kalkine do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations later.